Publication

The EORTC-DeCOG nomogram adequately predicts outcomes of patients with sentinel node-positive melanoma without the need for completion lymph node dissection

Verver, D., Rekkas, A., Garbe, C., van Klaveren, D., van Akkooi, A. C. J., Rutkowski, P., Powell, B. W. E. M., Robert, C., Testori, A., van Leeuwen, B. L., van der Veldt, A. A. M., Keilholz, U., Stadler, R., Eggermont, A. M. M., Verhoef, C., Leiter, U. & Grünhagen, D. J., Jul-2020, In : European Journal of Cancer. 134, p. 9-18 10 p.

Research output: Contribution to journalArticleAcademicpeer-review

APA

Verver, D., Rekkas, A., Garbe, C., van Klaveren, D., van Akkooi, A. C. J., Rutkowski, P., ... Grünhagen, D. J. (2020). The EORTC-DeCOG nomogram adequately predicts outcomes of patients with sentinel node-positive melanoma without the need for completion lymph node dissection. European Journal of Cancer, 134, 9-18. https://doi.org/10.1016/j.ejca.2020.04.022

Author

Verver, Daniëlle ; Rekkas, A ; Garbe, Claus ; van Klaveren, David ; van Akkooi, Alexander C J ; Rutkowski, Piotr ; Powell, Barry W E M ; Robert, Caroline ; Testori, Alessandro ; van Leeuwen, Barbara L ; van der Veldt, Astrid A M ; Keilholz, Ulrich ; Stadler, Rudolf ; Eggermont, Alexander M M ; Verhoef, Cornelis ; Leiter, Ulrike ; Grünhagen, Dirk J. / The EORTC-DeCOG nomogram adequately predicts outcomes of patients with sentinel node-positive melanoma without the need for completion lymph node dissection. In: European Journal of Cancer. 2020 ; Vol. 134. pp. 9-18.

Harvard

Verver, D, Rekkas, A, Garbe, C, van Klaveren, D, van Akkooi, ACJ, Rutkowski, P, Powell, BWEM, Robert, C, Testori, A, van Leeuwen, BL, van der Veldt, AAM, Keilholz, U, Stadler, R, Eggermont, AMM, Verhoef, C, Leiter, U & Grünhagen, DJ 2020, 'The EORTC-DeCOG nomogram adequately predicts outcomes of patients with sentinel node-positive melanoma without the need for completion lymph node dissection', European Journal of Cancer, vol. 134, pp. 9-18. https://doi.org/10.1016/j.ejca.2020.04.022

Standard

The EORTC-DeCOG nomogram adequately predicts outcomes of patients with sentinel node-positive melanoma without the need for completion lymph node dissection. / Verver, Daniëlle; Rekkas, A; Garbe, Claus; van Klaveren, David; van Akkooi, Alexander C J; Rutkowski, Piotr; Powell, Barry W E M; Robert, Caroline; Testori, Alessandro; van Leeuwen, Barbara L; van der Veldt, Astrid A M; Keilholz, Ulrich; Stadler, Rudolf; Eggermont, Alexander M M; Verhoef, Cornelis; Leiter, Ulrike; Grünhagen, Dirk J.

In: European Journal of Cancer, Vol. 134, 07.2020, p. 9-18.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

Verver D, Rekkas A, Garbe C, van Klaveren D, van Akkooi ACJ, Rutkowski P et al. The EORTC-DeCOG nomogram adequately predicts outcomes of patients with sentinel node-positive melanoma without the need for completion lymph node dissection. European Journal of Cancer. 2020 Jul;134:9-18. https://doi.org/10.1016/j.ejca.2020.04.022


BibTeX

@article{60b9f3e078f34f2baba8e28fcb0072fe,
title = "The EORTC-DeCOG nomogram adequately predicts outcomes of patients with sentinel node-positive melanoma without the need for completion lymph node dissection",
abstract = "Purpose: Based on recent advances in the management of patients with sentinel node (SN)-positive melanoma, we aimed to develop prediction models for recurrence, distant metastasis (DM) and overall mortality (OM).Methods: The derivation cohort consisted of 1080 patients with SN-positive melanoma from nine European Organization for Research and Treatment of Cancer (EORTC) centres. Prognostic factors for recurrence, DM and OM were studied with Cox regression analysis. Significant factors were incorporated in the models. Performance was assessed by discrimination (c-index) and calibration in cross-validation across centres. The models were externally validated using a prospective cohort consisting of 705 German patients with SN-positive: 473 trial participants of the German Dermatologic Cooperative Oncology Group study (DeCOG-SLT) and 232 screened patients. A nomogram was developed for graphical presentation.Results: The final model for recurrence and the calibrated models for DM and OM included ulceration, age, SN tumour burden and Breslow thickness. The models showed reasonable calibration. The c-index for the recurrence, DM and OM model was 0.68, 0.70 and 0.70, respectively, and 0.70, 0.72 and 0.74, respectively, in external validation. The EORTCDeCOG model identified a robust low-risk group, with all identified low-risk patients (approximately 4{\%} of the entire population) having a 5-year recurrence probability ofConclusions: The EORTC-DeCOG nomogram provides an adequate prognostic tool for patients with SN-positive melanoma, without the need for CLND. It showed consistent results across validation. The nomogram could be used for patient counselling and might aid in adjuvant therapy decision-making. (C) 2020 The Author(s). Published by Elsevier Ltd.",
keywords = "Melanoma, Sentinel lymph node, Nomogram, Prognosis, Adjuvant therapy, RESECTED STAGE-III, ADJUVANT THERAPY, CUTANEOUS MELANOMA, TUMOR BURDEN, BIOPSY, SURVIVAL, INTERFERON-ALPHA-2B, MULTICENTER, IPILIMUMAB, INTERVAL",
author = "Dani{\"e}lle Verver and A Rekkas and Claus Garbe and {van Klaveren}, David and {van Akkooi}, {Alexander C J} and Piotr Rutkowski and Powell, {Barry W E M} and Caroline Robert and Alessandro Testori and {van Leeuwen}, {Barbara L} and {van der Veldt}, {Astrid A M} and Ulrich Keilholz and Rudolf Stadler and Eggermont, {Alexander M M} and Cornelis Verhoef and Ulrike Leiter and Gr{\"u}nhagen, {Dirk J}",
note = "Copyright {\circledC} 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.",
year = "2020",
month = "7",
doi = "10.1016/j.ejca.2020.04.022",
language = "English",
volume = "134",
pages = "9--18",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "ELSEVIER SCI LTD",

}

RIS

TY - JOUR

T1 - The EORTC-DeCOG nomogram adequately predicts outcomes of patients with sentinel node-positive melanoma without the need for completion lymph node dissection

AU - Verver, Daniëlle

AU - Rekkas, A

AU - Garbe, Claus

AU - van Klaveren, David

AU - van Akkooi, Alexander C J

AU - Rutkowski, Piotr

AU - Powell, Barry W E M

AU - Robert, Caroline

AU - Testori, Alessandro

AU - van Leeuwen, Barbara L

AU - van der Veldt, Astrid A M

AU - Keilholz, Ulrich

AU - Stadler, Rudolf

AU - Eggermont, Alexander M M

AU - Verhoef, Cornelis

AU - Leiter, Ulrike

AU - Grünhagen, Dirk J

N1 - Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.

PY - 2020/7

Y1 - 2020/7

N2 - Purpose: Based on recent advances in the management of patients with sentinel node (SN)-positive melanoma, we aimed to develop prediction models for recurrence, distant metastasis (DM) and overall mortality (OM).Methods: The derivation cohort consisted of 1080 patients with SN-positive melanoma from nine European Organization for Research and Treatment of Cancer (EORTC) centres. Prognostic factors for recurrence, DM and OM were studied with Cox regression analysis. Significant factors were incorporated in the models. Performance was assessed by discrimination (c-index) and calibration in cross-validation across centres. The models were externally validated using a prospective cohort consisting of 705 German patients with SN-positive: 473 trial participants of the German Dermatologic Cooperative Oncology Group study (DeCOG-SLT) and 232 screened patients. A nomogram was developed for graphical presentation.Results: The final model for recurrence and the calibrated models for DM and OM included ulceration, age, SN tumour burden and Breslow thickness. The models showed reasonable calibration. The c-index for the recurrence, DM and OM model was 0.68, 0.70 and 0.70, respectively, and 0.70, 0.72 and 0.74, respectively, in external validation. The EORTCDeCOG model identified a robust low-risk group, with all identified low-risk patients (approximately 4% of the entire population) having a 5-year recurrence probability ofConclusions: The EORTC-DeCOG nomogram provides an adequate prognostic tool for patients with SN-positive melanoma, without the need for CLND. It showed consistent results across validation. The nomogram could be used for patient counselling and might aid in adjuvant therapy decision-making. (C) 2020 The Author(s). Published by Elsevier Ltd.

AB - Purpose: Based on recent advances in the management of patients with sentinel node (SN)-positive melanoma, we aimed to develop prediction models for recurrence, distant metastasis (DM) and overall mortality (OM).Methods: The derivation cohort consisted of 1080 patients with SN-positive melanoma from nine European Organization for Research and Treatment of Cancer (EORTC) centres. Prognostic factors for recurrence, DM and OM were studied with Cox regression analysis. Significant factors were incorporated in the models. Performance was assessed by discrimination (c-index) and calibration in cross-validation across centres. The models were externally validated using a prospective cohort consisting of 705 German patients with SN-positive: 473 trial participants of the German Dermatologic Cooperative Oncology Group study (DeCOG-SLT) and 232 screened patients. A nomogram was developed for graphical presentation.Results: The final model for recurrence and the calibrated models for DM and OM included ulceration, age, SN tumour burden and Breslow thickness. The models showed reasonable calibration. The c-index for the recurrence, DM and OM model was 0.68, 0.70 and 0.70, respectively, and 0.70, 0.72 and 0.74, respectively, in external validation. The EORTCDeCOG model identified a robust low-risk group, with all identified low-risk patients (approximately 4% of the entire population) having a 5-year recurrence probability ofConclusions: The EORTC-DeCOG nomogram provides an adequate prognostic tool for patients with SN-positive melanoma, without the need for CLND. It showed consistent results across validation. The nomogram could be used for patient counselling and might aid in adjuvant therapy decision-making. (C) 2020 The Author(s). Published by Elsevier Ltd.

KW - Melanoma

KW - Sentinel lymph node

KW - Nomogram

KW - Prognosis

KW - Adjuvant therapy

KW - RESECTED STAGE-III

KW - ADJUVANT THERAPY

KW - CUTANEOUS MELANOMA

KW - TUMOR BURDEN

KW - BIOPSY

KW - SURVIVAL

KW - INTERFERON-ALPHA-2B

KW - MULTICENTER

KW - IPILIMUMAB

KW - INTERVAL

U2 - 10.1016/j.ejca.2020.04.022

DO - 10.1016/j.ejca.2020.04.022

M3 - Article

C2 - 32454396

VL - 134

SP - 9

EP - 18

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

ER -

ID: 126996824